Blog
RSS FeedPosted by Michael Wonder on 25 Feb 2021
NHS patients to benefit from first full access deal in Europe for new CAR-T therapy recommended by NICE
25 February 2021 - NICE has agreed a managed access agreement, via the Cancer Drugs Fund with manufacturer Kite, so more ...
Posted by Michael Wonder on 24 Feb 2021
Tecartus recommended by NICE
24 February 2021 - Treatment with autologous anti-CD19-transduced CD3+ cells (brexucabtagene autoleucel) is recommended for use within the Cancer Drugs Fund ...
Posted by Michael Wonder on 15 Feb 2021
NICE rejects Lilly’s Verzenios for advanced breast cancer
15 February 2021 - The UK’s NICE has not recommended Eli Lilly’s Verzenios (abemaciclib) with fulvestrant for the treatment of ...
Posted by Michael Wonder on 04 Feb 2021
Thousands of lung cancer patients to benefit from life extending treatment
4 February 2021 - A potentially life extending treatment for some people with non-squamous, non-small-cell lung cancer will now be available ...
Posted by Michael Wonder on 01 Feb 2021
Determinants of managed entry agreements in the context of health technology assessment: a comparative analysis of oncology therapies in four countries
29 January 2021 - Managed entry agreements are increasingly used to address uncertainties arising in the health technology assessment process due ...
Posted by Michael Wonder on 27 Jan 2021
NICE recommends Revlimid for newly diagnosed multiple myeloma patients
27 January 2021 - Bristol Myers Squibb’s Revlimid (lenalidomide) has received a recommendation from the UK’s NICE for newly diagnosed ...
Posted by Michael Wonder on 26 Jan 2021
NICE publishes second appraisal consultation document for Zytiga
26 January 2021 - NICE has had another look at abiraterone acetate for the treatment of patients with newly diagnosed ...
Posted by Michael Wonder on 15 Jan 2021
NICE backs GSK’s Zejula in advanced ovarian cancer
15 January 2021 - The UK’s NICE has recommended the use of GlaxoSmithKline’s Zejula (niraparib) on the NHS for women ...
Posted by Michael Wonder on 08 Jan 2021
NICE no for BMS’ Opdivo for head and neck cancer
8 January 2021 - The UK’s NICE has turned down Bristol Myers Squibb’s immunotherapy Opdivo (nivolumab) for recurrent or metastatic ...
Posted by Michael Wonder on 11 Dec 2020
Alunbrig scores NICE backing for ALK positive lung cancer
11 December 2020 - Takeda’s Alunbrig (brigatinib) has been recommended by the UK’s NICE for patients with ALK positive advanced ...
Posted by Michael Wonder on 08 Dec 2020
NICE backs AstraZeneca's Calquence for chronic lymphocytic leukaemia
8 December 2020 - NICE has published preliminary guidelines backing use of AstraZeneca's Calquence (acalabrutinib) as an NHS funded treatment ...
Posted by Michael Wonder on 25 Nov 2020
Merck racks up another NICE recommendation for Keytruda
25 November 2020 - That makes it number 12. ...
Posted by Michael Wonder on 25 Nov 2020
NICE publishes final guidance on Nubeqa
25 November 2020 - NICE has completed its assessment of darolutamide for use in combination with androgen deprivation therapy for ...
Posted by Michael Wonder on 24 Nov 2020
NICE backs Braftovi for BRAF positive colorectal cancer
24 November 2020 - NICE has back Pierre Fabre’s Braftovi plus cetuximab for the treatment of BRAF positive metastatic colorectal ...
Posted by Michael Wonder on 24 Nov 2020
New option for people with difficult-to-treat multiple myeloma is recommended for use in Cancer Drugs Fund by NICE
24 November 2020 - Around 5,700 cases of multiple myeloma are diagnosed each year in the UK. ...